| Identification | Back Directory | [Name]
Zampilimab | [CAS]
2098280-42-1 | [Synonyms]
Zampilimab
Research Grade Zampilimab
Research Grade Zampilimab(DHD49201) |
| Hazard Information | Back Directory | [Uses]
Zampilimab (UCB-7858) is a monoclonal antibody against transglutaminase 2 (TG2). Zampilimab has potential application in renal transplant[1][2]. | [References]
[1] Tempest R, et al. The Biological and Biomechanical Role of Transglutaminase-2 in the Tumour Microenvironment. Cancers (Basel). 2021 Jun 3;13(11):2788. DOI:10.3390/cancers13112788
[2] Prat-Duran J, et al. Transglutaminase 2 as a novel target in chronic kidney disease - Methods, mechanisms and pharmacological inhibition. Pharmacol Ther. 2021 Jun;222:107787. DOI:10.1016/j.pharmthera.2020.107787
[3] Huang L, et al. The effect of TG2-inhibitory monoclonal antibody zampilimab on tissue fibrosis in human in vitro and primate in vivo models of chronic kidney disease. PLoS One. 2024 May 16;19(5):e0298864. |
|
| Company Name: |
Biolab Reagents
|
| Telephone: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
|